

SEQUENCE LISTING

<110> Sanofi-Aventis Deutschland GmbH

<120> Capping of unprotected amino groups during peptide synthesis

<130> 65946PEP

<160> 4

<170> PatentIn version 3.5

<210> 1

<211> 44

<212> PRT

<213> Artificial Sequence

<220>

<223> lixisenatide

<400> 1

His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Leu	Ser	Lys	Gln	Met	Glu	Glu
1				5					10					15	

Glu	Ala	Val	Arg	Leu	Phe	Ile	Glu	Trp	Leu	Lys	Asn	Gly	Gly	Pro	Ser
			20					25					30		

Ser	Gly	Ala	Pro	Pro	Ser	Lys	Lys	Lys	Lys	Lys	Lys
		35				40					

<210> 2

<211> 39

<212> PRT

<213> Heloderma suspectum

<220>

<223> exendin-4

<400> 2

His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Leu	Ser	Lys	Gln	Met	Glu	Glu
1				5					10					15	

Glu	Ala	Val	Arg	Leu	Phe	Ile	Glu	Trp	Leu	Lys	Asn	Gly	Gly	Pro	Ser
			20					25					30		

Ser	Gly	Ala	Pro	Pro	Pro	Ser
-----	-----	-----	-----	-----	-----	-----

35

<210> 3
<211> 39
<212> PRT
<213> Heloderma horridum

<220>
<223> exendin-3

<400> 3

His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35

<210> 4
<211> 30
<212> PRT
<213> human

<220>
<223> GLP-1(7-36)

<400> 4

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg
20 25 30